Core Viewpoint - The company announced the termination of the investment agreement to establish a joint venture with AstraZeneca due to significant market changes and high risks in the vaccine industry [1] Group 1: Joint Venture Details - The company planned to establish a joint venture with AstraZeneca focusing on vaccines, with a registered capital of 345 million RMB (approximately 50 million USD) [1] - Both the company and AstraZeneca were to hold 50% equity in the joint venture, with a total investment estimated at around 400 million USD (approximately 2.76 billion RMB) [1] Group 2: Termination of Agreement - The decision to terminate the investment agreement was made after careful evaluation and friendly negotiations among the parties involved [1] - The termination was approved in a board meeting held on February 6, 2026, and the company management was authorized to finalize and sign the relevant termination agreements [1]

Core Viewpoint - Kangtai Biological (300601.SZ) has achieved significant recognition in the field of technological innovation by winning the second prize of the Jiangsu Provincial Science and Technology Progress Award for its project on rapid confirmation and precise prevention of emerging viral infectious diseases [1][2] Group 1: Project Recognition and Achievements - The project, led by the Jiangsu Provincial Center for Disease Control and Prevention, addresses critical challenges in the prevention and control of emerging viral infectious diseases [2] - Kangtai's subsidiary, Beijing Minhai Biotechnology Co., Ltd., has previously received the second prize of the Beijing Science and Technology Progress Award and has been approved for the establishment of a key laboratory in synthetic immunology and vaccine manufacturing [1] Group 2: Technological Innovations - The project includes a highly efficient response system developed through a series of technical breakthroughs, with Kangtai providing key technological support through its inactivated enterovirus vaccine platform [2] - The company has successfully obtained clinical trial approval from the National Medical Products Administration for its bivalent and quadrivalent inactivated enterovirus vaccines, with the quadrivalent vaccine currently in Phase I clinical trials [2] Group 3: Market Position and Future Prospects - There are currently no approved bivalent or quadrivalent enterovirus vaccines available globally, indicating a significant market opportunity for Kangtai [2] - Successful development of these vaccines will enhance the company's multi-valent vaccine portfolio, strengthen its core competitiveness, and solidify its market position for sustainable growth [2]

Core Viewpoint - The company announced the termination of the investment agreement with AstraZeneca due to significant market changes and high risks in the vaccine industry [1] Group 1: Investment Agreement - The company planned to establish a joint venture with AstraZeneca focusing on vaccines, with a registered capital of 345 million RMB (approximately 50 million USD) [1] - Both the company and AstraZeneca were to hold 50% equity in the joint venture, with a total investment estimated at around 400 million USD (approximately 2.76 billion RMB) [1] - The decision to terminate the investment was made after careful evaluation and discussions among the parties involved, acknowledging the high risks associated with new investments in the vaccine sector [1] Group 2: Board Decisions - The termination of the investment agreement was approved during the company's eighth board meeting held on February 6, 2026 [1] - The board authorized the management to finalize and sign the relevant termination agreements with the partners [1]

Group 1 - The China Securities Regulatory Commission (CSRC) has issued supplementary material requirements for four companies, including Yifang Biotechnology, which is required to clarify compliance operations related to safety production [1] - Yifang Biotechnology has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities acting as its sole sponsor [1] - The CSRC has requested Yifang Biotechnology to provide legal opinions on several matters, including the company's business scope and compliance with foreign investment policies [1] Group 2 - As of December 24, 2025, the company has established a comprehensive and differentiated product pipeline, including two commercialized products and several products in various clinical stages [2] - The commercialized products include BPI-D0316 and D1553, while core clinical products include D-2570 and D-0502 [2] - The pipeline also features a clinical candidate product, D-0120, and three preclinical candidates: YF087, YF550, and YF057 [2]

Core Insights - The approval of VELSIPITY (Arginine Eculizumab Tablets) by the NMPA marks a significant advancement in the treatment of moderate to severe active ulcerative colitis (UC) in adults, addressing a critical gap in the market for patients unresponsive to traditional therapies [1][2][4] Group 1: Product Overview - VELSIPITY is a next-generation high-selectivity S1P receptor modulator, designed for once-daily oral administration, offering rapid onset and effective deep mucosal healing, with a strong safety profile [1][3] - The drug is projected to reach peak sales of 5 billion RMB, positioning it as a core product for the company following its success with renal disease treatment [1][6] Group 2: Market Context - The incidence of ulcerative colitis in China is rising, with an expected increase in patient numbers from approximately 980,000 in 2025 to about 1.5 million by 2031, highlighting the urgent need for effective treatments [2] - Current treatment options are limited, with existing therapies facing challenges such as limited efficacy, high relapse rates, and adverse reactions [2][5] Group 3: Clinical Efficacy - Clinical trials have demonstrated VELSIPITY's significant efficacy, with a clinical remission rate of 48.1% and a mucosal healing rate of 51.9% over 40 weeks of maintenance treatment [3][4] - The drug has been recognized in multiple international guidelines as a first-line treatment for ulcerative colitis, underscoring its clinical value [4] Group 4: Commercialization Strategy - The company has established a comprehensive A2MS operational system to facilitate the market entry of VELSIPITY, leveraging its scientific and commercial insights [5][6] - VELSIPITY is set to be included in the urgent import drug directory for clinical use in the Greater Bay Area in 2024, providing a first-mover advantage [6][7] Group 5: Financial Outlook - The approval of VELSIPITY enhances the company's revenue structure, with expectations of significant growth in revenue and profitability as it expands its product portfolio [6][7] - The company aims to achieve over 15 billion RMB in revenue by 2030, driven by a combination of existing and new product sales, with a projected compound annual growth rate exceeding 50% from 2025 to 2030 [7]

Group 1 - The China Securities Regulatory Commission (CSRC) has issued supplementary material requirements for four companies, including Yifang Biotechnology, which is required to clarify compliance operations related to safety production [1] - Yifang Biotechnology has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities as its sole sponsor [1] - The CSRC has requested Yifang Biotechnology to provide legal opinions regarding its business scope and whether it involves restricted foreign investment areas, as well as compliance with foreign investment policies [1] Group 2 - As of December 24, 2025, the company has established a comprehensive and differentiated product pipeline, including two commercialized products (Befotizumab and Gexorase), two core products in clinical stages (D-2570 and Terysqun), one clinical candidate (Dabinoside), and three preclinical candidates (YF087, YF550, and YF057) [2]

Group 1 - The core event involves a block trade of Jinbo Biological (stock code: 920982) on the Beijing Stock Exchange, with a closing price of 224.39 CNY per share [1] - The block trade occurred on February 6, 2026, with a transaction price of 297 CNY per share, representing a premium of 32.36% [1] - The total volume of the transaction was 55,000 shares, amounting to 16.335 million CNY [1] Group 2 - The buying brokerage was Caitong Securities Co., Ltd., specifically the Hangzhou Qiutao Road Securities Business Department [1] - The selling brokerage was Dongbei Securities Co., Ltd., from the Hangzhou Xinbei Road Securities Business Department [1]

Group 1 - The China Securities Regulatory Commission (CSRC) has issued supplementary material requirements for four companies, including Yifang Biotechnology, which is required to clarify compliance operations related to safety production [1] - Yifang Biotechnology has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities as its sole sponsor [1] - The CSRC requests Yifang Biotechnology to provide legal opinions regarding its business scope and whether it involves areas restricted for foreign investment, as well as compliance with foreign investment access policies [1] Group 2 - As of December 24, 2025, the company has established a comprehensive and differentiated product pipeline, including two commercialized products (Befotizumab and Gexorase), two core products in clinical stages (D-2570 and Terysqun), one clinical candidate (Dabinoside), and three preclinical candidates (YF087, YF550, and YF057) [2]

Core Viewpoint - The company is focusing on building a global health ecosystem through "platform integration and diagnostic integration," enhancing international business from "single-point cooperation" to "ecological collaboration" [2] Group 1: International Strategy - The company aims for significant development in overseas markets by 2025, steadily expanding its business footprint and improving global resource allocation efficiency [2] - The acquisition of Germany's inno-train Diagnostik GmbH in January is a key strategic move to strengthen the company's global presence in high-end blood molecular diagnostics [2] Group 2: Financial Practices - The company places high importance on asset impairment and goodwill assessment, ensuring that annual financial data strictly adheres to accounting standards and is audited [2]

★ 宏观动态 ★ 预制菜国家标准征求意见：中央厨房制作的菜肴等或不属于预制菜 2月6日，国家卫生健康委发布了《食品安全国家标准 预制菜》（征求意见稿），面向社会公开征求意见。标 准明确：①预制菜是以一种或多种食用农产品及其制品为原料，使用或不使用调味料等辅料，不添加防腐剂， 经工业化预加工(如搅拌，腌制，滚揉，成型，炒，炸，烤，煮，蒸等)制成，配以或不配以调味料包，加热或 熟制后方可食用的预包装菜肴产品。②预制菜不包括主食类食品、净菜类食品、即食食品和中央厨房制作的菜 肴。③尽量缩短预制菜的产品保质期，最长不应超过12个月。③不得使用防腐剂，尽可能减少食品添加剂的使 用。 大商所2026年春节期间交易时间安排：2月15日至2月23日休市，24日起照常开市 大连商品交易所2026年春节期间交易时间安排通知如下：2月15日（周日）至2月23日（周一）休市，2月24日 （周二）起照常开市。2月14日（周六）、2月28日（周六）为周末休市。2月13日（周五）晚上不进行夜盘交 易。2月24日（周二）所有合约集合竞价时间为上午08:55-09:00。2月24日（周二）当晚恢复夜盘交易。 上海黄金交易所：调整部分合约保证金 ...